Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus
Open Access
- 1 November 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (11) , 3754-3762
Abstract
Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant Staphylococcus aureus (MRSA). The population pharmacokinetics of arbekacin was investigated in the Japanese, using 353 patients infected with MRSA and 50 healthy or renally impaired volunteers. The age of the study population ranged from 8 to 95 years, and weight ranged from 10.8 to 107 kg. In total, 1,581 serum arbekacin concentrations were measured (primarily from routine patient care) and used to perform the present pharmacokinetic analysis. Drug concentration-time data were well described by a two-compartment open model. Factors influencing arbekacin pharmacokinetics were investigated using a nonlinear mixed-effect model analysis. The best-developed model showed that drug clearance (CL) was related to creatinine clearance (CL CR ), age, and body weight (WT), as expressed by CL (liter/h) = 0.0319CL CR + (26.5/age) (CL CR < 80 ml/min) and CL (liter/h) = 0.0130 CL CR + 0.0342WT + (26.5/age) (CL CR ≥ 80 ml/min). The volume of distribution for the central and peripheral compartments was different in healthy subjects and infected patients, and this difference was more pronounced among disease types. The elderly subjects (aged 80 years or over) exhibited, on average, a 19% greater volume for the central compartment. The volumes for the peripheral compartment were 50.6 liters in patients with pneumonia and 24.3 liters in patients with sepsis. The population pharmacokinetic parameters of arbekacin obtained here are useful for optimal use of this aminoglycoside in the treatment of MRSA-infected patients.Keywords
This publication has 41 references indexed in Scilit:
- Pharmacokinetic-Pharmacodynamic Relationship of Arbekacin for Treatment of Patients Infected with Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2006
- The effect of sepsis upon gentamicin pharmacokinetics in neonatesBritish Journal of Clinical Pharmacology, 2004
- Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in NeonatesAntimicrobial Agents and Chemotherapy, 2004
- Factors affecting gentamicin pharmacokinetics in septic patientsActa Anaesthesiologica Scandinavica, 1999
- Population pharmacokinetics of gentamicin in patients with cancerBritish Journal of Clinical Pharmacology, 1998
- Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 1995
- Gentamicin volume of distribution in critically ill septic patientsIntensive Care Medicine, 1990
- Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory ConcentrationThe Journal of Infectious Diseases, 1987
- An Overview of AmikacinTherapeutic Drug Monitoring, 1985
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976